DE60313434T2 - Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen - Google Patents

Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen Download PDF

Info

Publication number
DE60313434T2
DE60313434T2 DE60313434T DE60313434T DE60313434T2 DE 60313434 T2 DE60313434 T2 DE 60313434T2 DE 60313434 T DE60313434 T DE 60313434T DE 60313434 T DE60313434 T DE 60313434T DE 60313434 T2 DE60313434 T2 DE 60313434T2
Authority
DE
Germany
Prior art keywords
pyrimidin
growth factor
inhibitor
benzyloxyphenyl
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313434T
Other languages
German (de)
English (en)
Other versions
DE60313434D1 (de
Inventor
Charles Dean Newton Center STILES
Carlos Garcia-Echeverria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of DE60313434D1 publication Critical patent/DE60313434D1/de
Application granted granted Critical
Publication of DE60313434T2 publication Critical patent/DE60313434T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60313434T 2002-02-14 2003-02-14 Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen Expired - Lifetime DE60313434T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35691202P 2002-02-14 2002-02-14
US356912P 2002-02-14
PCT/EP2003/001507 WO2003068265A1 (en) 2002-02-14 2003-02-14 Methods and compositions for treating hyperproliferative conditions

Publications (2)

Publication Number Publication Date
DE60313434D1 DE60313434D1 (de) 2007-06-06
DE60313434T2 true DE60313434T2 (de) 2008-01-10

Family

ID=27734705

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313434T Expired - Lifetime DE60313434T2 (de) 2002-02-14 2003-02-14 Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen

Country Status (11)

Country Link
EP (1) EP1476192B1 (https=)
JP (1) JP5053503B2 (https=)
CN (1) CN100591355C (https=)
AT (1) ATE360442T1 (https=)
AU (1) AU2003205768A1 (https=)
BR (1) BR0307629A (https=)
CA (1) CA2476000A1 (https=)
DE (1) DE60313434T2 (https=)
ES (1) ES2283744T3 (https=)
PT (1) PT1476192E (https=)
WO (1) WO2003068265A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
DE4129533A1 (de) * 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CN1117097C (zh) * 1998-05-29 2003-08-06 北京金赛狮生物制药技术开发有限责任公司 类胰岛素生长因子受体基因的反义核酸的抑癌作用

Also Published As

Publication number Publication date
BR0307629A (pt) 2005-01-11
ES2283744T3 (es) 2007-11-01
CN100591355C (zh) 2010-02-24
EP1476192B1 (en) 2007-04-25
JP2005517040A (ja) 2005-06-09
CA2476000A1 (en) 2003-08-21
DE60313434D1 (de) 2007-06-06
AU2003205768A1 (en) 2003-09-04
JP5053503B2 (ja) 2012-10-17
EP1476192A1 (en) 2004-11-17
PT1476192E (pt) 2007-07-26
CN1630534A (zh) 2005-06-22
ATE360442T1 (de) 2007-05-15
WO2003068265A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
DE60313434T2 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
DE60127970T2 (de) Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
DE69227571T2 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivität und zur behandlung von tumoren
DE3827974A1 (de) Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
CA2810339A1 (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
DE60125159T2 (de) Neue kombination von einem beta-blocker und einem cholesterin-senkenden mittel
DE69920455T2 (de) Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
US20050215564A1 (en) Methods and compositions for treating hyperproliferative conditions
DE60204694T2 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
JP2009532497A (ja) 癌を処置するための治療剤の組合せ
US5116600A (en) Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds
DE60212415T2 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
DE2431558A1 (de) Arzneimittel zur behandlung von psoriasis
DE2401446A1 (de) Pharmazeutische zubereitungen zur linderung von hautproliferationserkrankungen
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung
EP0019586A1 (de) Neue antithrombotische Kombinationspräparate
EP0331871A2 (de) Antipsychotisch wirksames Imidazobenzodiazepin
DE69112376T3 (de) Verbesserte Therapiemethode.
DE60313344T2 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
DE60114473T2 (de) Disubstituierte 7,9-guaninium halogenide als telomeraseinhibitoren
DE3844839C2 (de) Verwendung von Imexon als Immunsuppressivum
DE3825667A1 (de) Verwendung von imexon als immunsuppressivum
DE10140421A1 (de) Neue Kombination
DE3311355A1 (de) Arzneimittel mit einer die atheroprotektiven high density lipoproteine steigernden wirkung, enthaltend 2,6-bis-diaethanolamino-4,8-dipiperidino-pyrimido (5,4-d)-pyrimidin
DE3833392A1 (de) Verwendung von pyrimido(5,4-d)pyrimidinen zur verhinderung der primaeren und sekundaeren resistenz bei der chemotherapie und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN